Validation of a volunteer model of cholera with frozen bacteria as the challenge

Infection and Immunity

Volumn 66, Issue 5, 1998, Pages 1968-1972

  Sack, David A ^a   Tacket, Carol O ^b   Cohen, Mitchell B ^c   Sack, R Bradley ^a   Losonsky, Genevieve A ^b   Shimko, Janet ^a   Nataro, James P ^b   Edelman, Robert ^b   Levine, Myron M ^b   Giannella, Ralph A ^c   Schiff, Gilbert ^c   Lang, Dennis ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACTERIAL VIRULENCE; CHOLERA; DIARRHEA; DISEASE SEVERITY; FEVER; HUMAN; INOCULATION; NORMAL HUMAN; PRIORITY JOURNAL; VIBRIO CHOLERAE;

VIBRIO CHOLERAE;

EID: 0031900841     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.5.1968-1972.1998     Document Type: Article

References (17)

1. Barua, D., and A. S. Paguio. 1977. ABO blood groups and cholera. Ann. Hum. Biol. 4:489-492.
2. Black, R. E., M. M. Levine, M. L. Clements, C. R. Young, A. M. Svennerholm, and J. Holmgren. 1987. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun. 55:1116-1120.
3. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, M. R. Khan, S. Huda, F. Ahmed, J. Gomes, M. R. Rao, and A. M. Svennerholm. 1989. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J. Infect. Dis. 159:770-773.
4. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, M. R. Khan, B. F. Stanton, M. Ali, F. Ahmed, M. Yunus, and B. A. Kay. 1988. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. Lancet i:1375-1379.
5. Clements, M. L., M. M. Levine, C. R. Young, R. E. Black, Y. L. Lim, R. M. Robins-Browne, and J. P. Craig. 1982. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J. Infect. Dis. 145:465-473.
6. Glass, R. I., S. Becker, M. I. Huq, B. J. Stoll, M. U. Khan, M. H. Merson, J. V. Lee, and R. E. Black. 1982. Endemic cholera in rural Bangladesh, 1966-1980. Am. J. Epidemiol. 116:959-970.
7. Goma Epidemiology Group. 1995. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994? Lancet 345:339-344.
8. Lagos, R., A. Avendano, V. Prado, I. Horwitz, S. Wasserman, G. Losonsky, S. J. Cryz, Jr., J. B. Kaper, and M. M. Levine. 1995. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect. Immun. 63:707-709.
9. Levine, M. M., and J. B. Kaper. 1993. Live oral vaccines against cholera: an update. Vaccine 11:207-212.
10. Levine, M. M., J. B. Kaper, D. A. Herrington, J. M. Ketley, G. Losonsky, C. O. Tacket, B. Tall, and S. J. Cryz, Jr. 1988. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines. CVD 103 and CVD 103-HgR. Lancet ii:467-470.
11. Levine, M. M., C. R. Young, R. E. Black, Y. Takeda, and R. A. Finkelstein. 1985. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J. Clin. Microbiol. 21:174-179.
12. Losonsky, G. A., J. Yunyongying, V. Lim, M. Reymann, Y. L. Lim, S. S. X. Wasserman, and M. M. Levine. 1996. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun. 64:10-15.
13. Sack, D. A., J. D. Clemens, S. Huda, J. R. Harris, M. R. Khan, J. Chakraborty, M. Yunus, J. Gomes, O. Siddique, F. Ahmed, B. Kay, F. van Loon, M. R. Rao, A. M. Svennerholm, and J. Holmgren. 1991. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J. Infect. Dis. 164:407-411.
14. Tacket, C. O., B. Forrest, R. Morona, S. R. Attridge, J. LaBrooy, B. D. Tall, M. Reymann, D. Rowley, and M. M. Levine. 1990. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect. Immun. 58:1620-1627.
15. Tacket, C. O., G. Losonsky, J. P. Nataro, L. Comstock, J. Michalski, R. Edelman, J. B. Kaper, and M. M. Levine. 1995. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J. Infect. Dis. 172:883-886.
16. Tacket, C. O., G. Losonsky, J. P. Nataro, S. J. Cryz, Jr., R. Edelman, J. B. Kaper, and M. M. Levine. 1992. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166:837-841.
17. Tauxe, R. V., and P. A. Blake. 1902. Epidemic cholera in Latin America. JAMA 267:1388-1390.